Lilly Provides Regulatory Update On Two Key Drugs: Zyprexa LAI, Byetta LAR
Firm responds to FDA’s “complete response” letter for the long-acting atypical antipsychotic and anticipates a six-month review.
Firm responds to FDA’s “complete response” letter for the long-acting atypical antipsychotic and anticipates a six-month review.